Skip to content

How To Fight The Innovation Antibodies And Win

Phil McKinney
Phil McKinney
1 min read
How To Fight The Innovation Antibodies And Win

The antagonist of the innovator is the corporate antibody.

Much like antibodies in our immune system attack and destroy foreign objects that might harm the body, “antibodies” in your organization identify and neutralize forces that threaten to destabilize a company. And in much the same way as antibodies can damage the very thing they seek to protect — for instance when they cause the body to reject a transplanted organ — corporate antibodies can stunt a company’s growth (and not address the innovators dilemma) when the shut down the fresh ideas and unconventional thinkers it so badly needs.

Some of the types of corporate antibodies are:

  • The Ego Antibody
  • The Fatigued Antibody
  • The No-Risk Antibody
  • The Comfort Antibody

Antibodies are the roadblock to innovation.

Need to fight the innovation antibodies? Then listen to this weeks show ...


[social align="center"]

Studio SessionsPast ShowsantibodiesCriticsIdea KillerInnovationunconventional thinkers

Phil McKinney Twitter

Phil McKinney is an innovator, podcaster, author, and speaker. He is the retired CTO of HP. Phil's book, Beyond The Obvious, shares his expertise and lessons learned on innovation and creativity.

Comments


Related Posts

Why Most Organizations Aren't Funding Innovation

Without a clear definition, innovation investment is meaningless.

Why Most Organizations Aren't Funding Innovation

R&D Spending Is the Most Misleading Number in Business

The government collects the real R&D split from every public company. It's locked away by federal law. Here's how to estimate it anyway.

The Innovators Studio is available on Apple, Spotify and YouTube. Subscribe Today.

The Innovation Metric Bill Hewlett and Dave Packard Used

HP used this R&D benchmark for decades and still managed to forget it. Most companies never found it.

Image of Bill Hewlett and David Packard sharing a secret